Stockscreener 앱 받기
14.85
0.27%
-0.04
시간 외 거래:
14.85
전일 마감가:
$14.89
열려 있는:
$14.77
하루 거래량:
1.46M
Relative Volume:
0.88
시가총액:
$2.52B
수익:
-
순이익/손실:
$-382.71M
주가수익비율:
-5.6679
EPS:
-2.62
순현금흐름:
$-325.64M
1주 성능:
+2.70%
1개월 성능:
-2.43%
6개월 성능:
-47.34%
1년 성능:
-43.77%
1일 변동 폭
$14.29
$15.02
1주일 범위
$13.79
$15.22
52주 변동 폭
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
14.85 | 2.47B | 0 | -382.71M | -325.64M | -2.62 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - MSN
Immunovant price target lowered to $35 from $51 at H.C. Wainwright - TipRanks
Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position - TipRanks
Immunovant Inc reports results for the quarter ended March 31Earnings Summary - TradingView
H.C. Wainwright Adjusts Price Target for Immunovant (IMVT) Amid Future Prospects | IMVT Stock News - GuruFocus
Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st
Immunovant (NASDAQ:IMVT) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Immunovant, Inc. Reports Strategic Progress and Financial Results - TipRanks
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - PR Newswire
Immunovant, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
Immunovant, Inc. SEC 10-K Report - TradingView
Immunovant (IMVT) Secures Strong Financial Position with $714 Million in Cash | IMVT Stock News - GuruFocus
Earnings Flash (IMVT) IMMUNOVANT INC. Reports Q4 Loss $0.64 Per Share, vs. FactSet Est of $-0.71 - marketscreener.com
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 - Yahoo Finance
Immunovant (IMVT) to Release Earnings on Wednesday - Defense World
Bank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
(IMVT) Trading Advice - news.stocktradersdaily.com
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm - Business Wire
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Northern Trust Corp - Defense World
Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey
The Manufacturers Life Insurance Company Has $889,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Smart Money Ratings For 20 Most Undervalued Stocks - Insider Monkey
Immunovant Inc (NASDAQ: IMVT) Is The Among Hot Stock Right Now - Stocksregister
Dimensional Fund Advisors LP Sells 58,463 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey
Raymond James Financial Inc. Buys Shares of 20,382 Immunovant, Inc. (NASDAQ:IMVT) - Defense World
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Investor’s Delight: Immunovant Inc (IMVT) Closes Weak at 15.22, Down -3.67 - DWinneX
Ins & Outs: Biopharma players shuffle c-suite ranks - BioProcess International
(IMVT) Investment Analysis - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Wells Fargo & Company MN - Defense World
A company insider recently sold 1,925 shares of Immunovant Inc [IMVT]. Should You Sale? - knoxdaily.com
IMVT’s Stock Market Adventure: -34.80% YTD Growth Amidst Volatility - investchronicle.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Perhaps timely catching Immunovant Inc (IMVT) would be a good idea - Sete News
Immunovant registers shares for selling stockholders - MSN
Potential Price Increase for Immunovant Inc (IMVT) After Recent Insider Activity - knoxdaily.com
Market Watch Highlights: Immunovant Inc (IMVT) Ends on an Downturn Note at 14.72 - DWinneX
Stock Market Recap: Immunovant Inc (IMVT) Concludes at 14.58, a -7.60 Surge/Decline - DWinneX
Renaissance Technologies LLC Sells 108,100 Shares of Immunovant, Inc. (NASDAQ:IMVT) - The AM Reporter
Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Average PT from Analysts - Defense World
Immunovant’s (IMVT) “Neutral” Rating Reiterated at UBS Group - Defense World
Immunovant Inc [IMVT] Records 50-Day SMA of $18.03 - knoxdaily.com
All change at Immunovant as Pete Salzmann retires - The Pharma Letter
UBS Downgrades Immunovant to Neutral, Price Target is $17 - marketscreener.com
Upward Trajectory: Immunovant Inc (IMVT) Posts a Slidee, Closing at 14.46 - DWinneX
Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Syndrome News
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):